Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Tyra Biosciences Inc (TYRA)

Tyra Biosciences Inc (TYRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights PR Newswire - Mon Mar 2, 3:05PM CST

- Launched " dabogratinib 3x3 "  strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -

TYRA : 37.15 (-2.70%)
Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium PR Newswire - Mon Feb 23, 4:30PM CST

CARLSBAD, Calif. , Feb. 23, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...

TYRA : 37.15 (-2.70%)
Tyra Biosciences to Participate in Upcoming Investor Conferences PR Newswire - Thu Feb 19, 3:05PM CST

CARLSBAD, Calif. , Feb. 19, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...

TYRA : 37.15 (-2.70%)
Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer PR Newswire - Mon Dec 1, 2025

CARLSBAD, Calif. , Dec. 1, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...

TYRA : 37.15 (-2.70%)
Medical Laboratory by Gorodenkoff via Shutterstock
3 Biotech Stocks Wall Street Analysts Predict Will More Than Double Barchart - Thu Nov 20, 2025

What makes analysts so bullish about these three names from the sector?

MEHCQ : 3.5000 (-2.78%)
GHRS : 13.97 (-5.67%)
TYRA : 37.15 (-2.70%)
DMAC : 6.76 (-3.70%)
XBI : 120.31 (-1.65%)
Tyra Biosciences Announces Participation at Upcoming Investor Events PR Newswire - Wed Nov 12, 2025

CARLSBAD, Calif. , Nov. 12, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...

TYRA : 37.15 (-2.70%)
Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights PR Newswire - Wed Nov 5, 2025

- Dosed first patients with dabogratinib in BEACH301 and SURF302; interim results from both studies expected in 2026 -

TYRA : 37.15 (-2.70%)
Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia PR Newswire - Thu Aug 21, 2025

-Dabogratinib is the only oral FGFR3-selective inhibitor in clinical development for achondroplasia-

TYRA : 37.15 (-2.70%)
Tyra Biosciences Announces Participation at Upcoming Investor Events PR Newswire - Wed Aug 20, 2025

CARLSBAD, Calif. , Aug. 20, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines...

TYRA : 37.15 (-2.70%)
Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights PR Newswire - Thu Aug 14, 2025

- Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) -

TYRA : 37.15 (-2.70%)

Barchart Exclusives

2 Top Defense Stocks to Buy Now as the Military Works to Reopen the Strait of Hormuz Barchart - 56 minutes ago
These two large defense contractors have strong, positive catalysts and attractive valuations. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.